150 related articles for article (PubMed ID: 35933271)
1. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
[TBL] [Abstract][Full Text] [Related]
2. The Impact on Cost-Effectiveness of Accounting for Generic Drug Pricing: Four Case Studies.
Cohen JT
Value Health; 2023 Mar; 26(3):344-350. PubMed ID: 36336585
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?
McQueen RB; Anderson KE; Levy JF; Carlson JJ
Pharmacoeconomics; 2023 Mar; 41(3):321-327. PubMed ID: 36656509
[TBL] [Abstract][Full Text] [Related]
4. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications.
Neumann PJ; Podolsky MI; Basu A; Ollendorf DA; Cohen JT
Value Health; 2022 Jan; 25(1):59-68. PubMed ID: 35031100
[TBL] [Abstract][Full Text] [Related]
5. The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics.
Kogut SJ; Campbell JD; Pearson SD
Value Health; 2023 Mar; 26(3):378-383. PubMed ID: 36566884
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Value-Based Price for 48 High-Technology Medical Devices.
Hyeraci G; Trippoli S; Rivano M; Messori A
Cureus; 2023 Jun; 15(6):e39934. PubMed ID: 37287820
[TBL] [Abstract][Full Text] [Related]
7. Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.
Hoyle M
Pharmacoeconomics; 2011 Jan; 29(1):1-15. PubMed ID: 21142275
[TBL] [Abstract][Full Text] [Related]
8. Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions.
Puls M; Horscroft J; Kearns B; Gladwell D; Church E; Johannesen K; Malcolm B; Borrill J
Value Health; 2024 Jul; 27(7):978-985. PubMed ID: 38513883
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
10. Future drug prices and cost-effectiveness analyses.
Hoyle M
Pharmacoeconomics; 2008; 26(7):589-602. PubMed ID: 18563950
[TBL] [Abstract][Full Text] [Related]
11. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing.
Alkhatib NS; Ramos K; Erstad B; Slack M; McBride A; Bhattacharjee S; Abraham I
J Med Econ; 2020 Nov; 23(11):1215-1222. PubMed ID: 32845794
[TBL] [Abstract][Full Text] [Related]
12. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
[TBL] [Abstract][Full Text] [Related]
13. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.
Yeung K; Li M; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1010-1015. PubMed ID: 28944729
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
Zueger PM; Schultz NM; Lee TA
Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports.
Bloudek LM; Nguyen V; Grueger J; Sullivan SD
Value Health; 2021 Jun; 24(6):789-794. PubMed ID: 34119076
[TBL] [Abstract][Full Text] [Related]
17. How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality.
Russo P
Glob Reg Health Technol Assess; 2022; 9():31-35. PubMed ID: 36628320
[TBL] [Abstract][Full Text] [Related]
18. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
19. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
20. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
